Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. ACN
3. NVDA
4. MU
5. GOOGL
6. APGE
7. DFTX
8. RGNX
9. LCO
10. KR

Go back to Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
AGIOS PHARM (NASDAQ: AGIO) Delayed: 35.16 +1.00 (2.93%)
Previous Close $34.16    52 Week High $71.49 
Open $34.30    52 Week Low $33.50 
Day High $35.53    P/E N/A 
Day Low $34.30    EPS $-1.18 
Volume 355,558